Score Overview
PeriodNet IncomeRevenueScoreGrowthTrendConsistencyGrowthTrendConsistency
5 Years
4.6
-236.12%
60%
—
10x
60%
—
5 Years
Score4.6
Net Growth-236.12%
Net Trend60%
Net Income Consistency—
Rev Growth10x
Rev Trend60%
Revenue Consistency—
Tarsus Pharmaceuticals Inc fundamental performance
Between 2020 and 2025, revenue grew from $ 33M to $ 451M and net income went from -$ 26M to -$ 66M. Revenue increased in 3 of those 5 years; net income in 3.
Tarsus Pharmaceuticals Inc currently holds a 5-year HDB Score of 4.6 out of 10. How the HDB Score is calculated.
Net Income x Stock Price
Historical Returns
| Period | Price | Return |
|---|---|---|
Last Price2026-08-12 | $ 70.02 | — |
1 Year2025-08-12 | $ 51.36 | 36.32% |
5 Years2021-08-12 | $ 26.25 | 166.72% |
All Time2020-10-16 | $ 20.58 | 240.21% |
| Period | Last Price2026-08-12 | 1 Year2025-08-12 | 5 Years2021-08-12 | All Time2020-10-16 |
|---|---|---|---|---|
| Price | $ 70.02 | $ 51.36 | $ 26.25 | $ 20.58 |
| Return | — | 36.32% | 166.72% | 240.21% |
Prices are split & dividend adjusted. All values are reported in USD.
Fundamental Data
| Year | |||
|---|---|---|---|
| 2026 | $ 606M | -$ 46M | $ 449M |
| 2025 | $ 451M | -$ 66M | $ 417M |
| 2024 | $ 182M | -$ 115M | $ 291M |
| 2023 | $ 17M | -$ 135M | $ 227M |
| 2022 | $ 25M | -$ 62M | $ 217M |
| 2021 | $ 57M | -$ 13M | $ 171M |
| IPO2020 | $ 33M | -$ 26M | $ 168M |
Explore beyond TARS
You're looking at Tarsus Pharmaceuticals Inc. Members apply the same fundamental framework across all 3,860 companies we cover.
- Every HDB Score — 1, 5, 10, 20 and 30 years, plus all-time
- Revenue and Net Income Consistency for every period
- Rank all 3,860 companies by any metric, not just three
- Filter by sector and currency, and page through the whole list
- Track your holdings in a portfolio
$99/year $149 founding price
Unlock Holder Dashboard30-day money-back guarantee.
